- 5/10/16: Looking to accelerate its debt reduction plan, Valeant Pharmaceuticals (NYSE:VRX) is considering the sale of Egyptian drugmaker Amoun Pharmaceutical, which it acquired for $800M in July 2015. Goldman Sachs is advising. Valeant also disclosed that it will pay $54M to settle civil charges that its Salix unit paid illegal kickbacks to induce doctors to prescribe seven of its products.
Saturday, June 11, 2016
Valeant (VRX) news
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment